Evolution of breast cancer therapeutics: Breast tumour kinase’s role in breast cancer and hope for breast tumour kinase targeted therapy

Figure 1 Breast tumour kinase domain structure. Full length Brk/PTK6 and short isoform ALT-PTK6 structure indicating the SH3 domain (green), SH2 domain (orange) and a tyrosine kinase domain or proline rich sequence (blue). Underneath is indicated the cDNA structure of both forms, with each box indicating each exon (total of 8 exons). ALT-PTK6 has deletion at exon 2 and lacks SH2 domain due to shift in open reading frame, which gives a proline rich sequence at exon 3 instead. PTK6: Protein tyrosine kinase 6; Brk: Breast tumour kinase.

Figure 2 Breast tumour kinase and cancer hallmarks. Brk and cancer hallmarks. The original six cancer hallmarks described by Hannahan and Weinberg (2001)[96] are illustrated along with a summary of Brk’s role in their regulation. Brk: Breast tumour kinase.